Three good reasons for heart surgeons to understand cardiac metabolism

European Journal of Cardio-thoracic Surgery

Volumn 33, Issue 5, 2008, Pages 862-871

  Doenst, Torsten ^a   Bugger, Heiko ^a   Schwarzer, Michael ^a   Faerber, Gloria ^a   Borger, Michael A ^a   Mohr, Friedrich W ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Cardiac surgery; Hyperglycemia; Metabolic drugs; Metabolism; Outcomes

Indexed keywords

ADENOSINE TRIPHOSPHATE; ETOMOXIR; INSULIN; TRIMETAZIDINE;

ANGINA PECTORIS; CARDIOPLEGIA; ENERGY CONSUMPTION; ENERGY METABOLISM; ENERGY RESOURCE; FATTY ACID OXIDATION; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART PROTECTION; HEART SURGERY; HUMAN; HYPERGLYCEMIA; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; RISK FACTOR; SURGEON; SURGICAL TECHNIQUE; TREATMENT OUTCOME;

ENERGY METABOLISM; GLUCOSE; HEART ARREST, INDUCED; HUMANS; MYOCARDIAL CONTRACTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; THORACIC SURGERY;

EID: 41949092931     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2008.02.015     Document Type: Review

References (111)

1. Taegtmeyer H. Energy metabolism of the heart: from basic concepts to clinical applications. Curr Prob Cardiol 19 (1994) 57-116
2. Taegtmeyer H. Fueling the heart: multiple roles for cardiac metabolism. In: Willerson J.T., Cohn J.N., Wellens H.J.J., and Holmes D.R. (Eds). Cardiovascular medicine. 3rd ed. (2007), Springer-Verlag, London 1157-1175
3. Holman G.D., and Kasuga M. From receptor to transporter: insulin signalling to glucose transport. Diabetologia 40 (1997) 991-1003
4. Cushman S.W., and Wardzala L.J. Potential mechanism of insulin action on glucose transport in the isolated rat adipose cell. J Biol Chem 255 (1980) 4755-4762
5. Depre C., Vanoverschelde J.L.J., and Taegtmeyer H. Glucose for the heart. Circulation 99 (1999) 578-588
6. Schaffer J.E., and Lodish H.F. Expression cloning and characterization of a novel adipocyte long chain fatty acid transport protein. Cell 79 (1994) 427-436
7. Dyck J.R., Barr A.J., Barr R.L., Kolattukudy P.E., and Lopaschuk G.D. Characterization of cardiac malonyl-CoA decarboxylase and its putative role in regulating fatty acid oxidation. Am J Physiol 275 (1998) H2122-H2129
8. Dyck J.R., and Lopaschuk G.D. AMPK alterations in cardiac physiology and pathology: enemy or ally?. J Physiol 574 (2006) 95-112
9. Kelly D.P., and Scarpulla R.C. Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. Genes Dev 18 (2004) 357-368
10. Lopaschuk G.D., Belke D.D., Gamble J., Itoi T., and Schonekess B.O. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim Biophys Acta 1213 (1994) 263-276
11. Saks V, Favier R, Guzun RS, U, Wallimann T. Molecular system bioenergetics: regulation of substrate supply in response to heart energy demands. J Physiol 2006;577:769-77.
12. Russell R.R., Bergeron R., Shulman G.I., and Young L.H. Translocation of myocardial GLUT4 and increased glucose uptake through activation of AMPK by AICAR. Am J Physiol 277 (1999) H643-H649
13. Tian R., and Balschi J.A. Interaction of insulin and AMPK in the ischemic heart: another chapter in the book of metabolic therapy?. Circ Res 99 (2006) 3-5
14. Doenst T., and Taegtmeyer H. α-Adrenergic stimulation mediates glucose uptake through phosphatidylinositol 3-kinase in rat heart. Circ Res 84 (1999) 467-474
15. Fischer Y., Kamp J., Pöpping S., Rose H., Carpene C., and Kammermeier H. Signals mediating stimulation of cardiomyocyte glucose transport by the alpha-adrenergic agonist phenylephrine. Am J Physiol 270 (1996) C1211-C1220
16. Fischer Y., Thomas J., Holman G.D., Rose H., and Kammermeier H. Contraction-independent effects of catecholamines on glucose transport in isolated rat cardiomyocytes. Am J Physiol 270 (1996) C1204-C1210
17. 2+ and insulin on 2-deoxyglucose uptake and phosphorylation in perfused rat heart. Biochim Biophys Acta 889 (1986) 225-235
18. Clark M., and Patten G.S. Adrenergic regulation of glucose metabolism in rat heart. J Biol Chem 259 (1984) 15204-15211
19. Baumann C.A., Ribon V., Kanzaki M., Thurmond D.C., Mora S., Shigematsu S., Bickel P.E., Pessin J.E., and Saltiel A.R. CAP defines a second signalling pathway required for insulin-stimulated glucose transport. Nature 407 (2000) 202-206
20. Shulman G.I. Unraveling the cellular mechanisms of insulin resistance in humans: New insights from magnetic resonance spectroscopy. Physiology 19 (2004) 183-190
21. Dresner A., Laurent D., Marcucci M., Griffin M.E., Dufour S., Cline G.W., Slezak L.A., Andersen D.K., Hundal R.S., Rothman D.L., Petersen K.F., and Shulman G.I. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3 kinase activity. J Clin Invest 103 (1999) 253-259
22. Lopaschuk G.D. Optimizing cardiac fatty acid and glucose metabolism as an approach to treating heart failure. Semin Cardiothorac Vasc Anesth 10 (2006) 228-230
23. Boudina S., and Abel E.D. Diabetic cardiomyopathy revisited. Circulation 115 (2007) 3213-3223
24. Boudina S., Sena S., Theobald H., Sheng X., Wright J.J., Hu X.X., Aziz S., Johnson J.I., Bugger H., Zaha V.G., and Abel E.D. Mitochondrial energetics in the heart in obesity-related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins. Diabetes 56 (2007) 2457-2466
25. Taegtmeyer H. Switching metabolic genes to build a better heart. Circulation 106 (2002) 2043-2045
26. Turcani M., and Rupp H. Modification of left ventricular hypertrophy by chronic etomoxir treatment. Br J Pharmacol 126 (1999) 501-507
27. Liao R., Jain M., Cui L., D'Agostino J., Aiello F., Luptak I., Ngoy S., Mortensen R.M., and Tian R. Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice. Circulation 106 (2002) 2125-2131
28. Lopaschuk G.D. Optimizing cardiac energy metabolism: how can fatty acid and carbohydrate metabolism be manipulated?. Coron Artery Dis 12 (2001) S8-S11
29. Garnier A., Fortin D., Delomenie C., Momken I., Veksler V., and Ventura-Clapier R. Depressed mitochondrial transcription factors and oxidative capacity in rat failing cardiac and skeletal muscles. J Physiol 551 (2003) 491-501
30. Stanley W.C., Recchia F.A., and Lopaschuk G.D. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 85 (2005) 1093-1129
31. Finck B.N., and Kelly D.P. PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest 116 (2006) 615-622
32. Bugger H., Zaha V., and Doenst T. Uncoordinate regulation of PGC-1α and respiratory chain gene expression in the development of heart failure in rats. Circulation 112 (2005) I-512
33. Ashrafian H., Frenneaux M.P., and Opie L.H. Metabolic mechanisms in heart failure. Circulation 116 (2007) 434-448
34. Bell D.S. Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 26 (2003) 2433-2441
35. Marshall J.D., Bronson R.T., Collin G.B., Nordstrom A.D., Maffei P., Paisey R.B., Carey C., Macdermott S., Russell-Eggitt I., Shea S.E., Davis J., Beck S., Shatirishvili G., Mihai C.M., Hoeltzenbein M., Pozzan G.B., Hopkinson I., Sicolo N., Naggert J.K., and Nishina P.M. New Alström syndrome phenotypes based on the evaluation of 182 cases. Arch Intern Med 165 (2005) 675-683
36. McQueen A.P., Zhang D., Hu P., Swenson L., Yang Y., Zaha V.G., Hoffman J.L., Yun U.J., Chakrabarti G., Wang Z., Albertine K.H., Abel E.D., and Litwin S.E. Contractile dysfunction in hypertrophied hearts with deficient insulin receptor signaling: possible role of reduced capillary density. J Mol Cell Cardiol 39 (2005) 882-892
37. Taegtmeyer H., Wilson C.R., Razeghi P., and Sharma S. Metabolic energetics and genetics in the heart. Ann N Y Acad Sci 1047 (2005) 208-218
38. Lopaschuk G.D. Alterations in fatty acid oxidation during reperfusion of the heart after myocardial ischemia. Am J Cardiol 80 (1997) 11A-16A
39. Lopaschuk G.D. Regulation of carbohydrate metabolism in ischemia and reperfusion. Am Heart J 139 (2000) S115-S119
40. Taegtmeyer H., King L.M., and Jones B.E. Energy substrate metabolism, myocardial ischemia, and targets for pharmacotherapy. Am J Cardiol 82 (1998) 54K-60K
41. Weiss J., and Hiltbrand B. Functional compartmentation of glycolytic versus oxidative metabolism in isolated rabbit heart. J Clin Invest 75 (1985) 436-447
42. Bretschneider H. Überlebenszeit und Wiederbelebungszeit des Herzens bei Normo- und Hypothermie; 1964.
43. Bretschneider H.J., Hubner G., Knoll D., Lohr B., Nordbeck H., and Spieckerman P.G. Myocardial resistance and tolerance to ischemia: physiological and chemical basis. J Cardiovasc Surg 16 (1975) 241-260
44. Chevion M, Jiang Y, Har-El R, Berenshtein E, Uretzky G, N K. Copper and iron are mobilized following myocardial ischemia: possible predictive criteria for tissue injury. Proc Nat Acad Sci U S A 1993;90:1102-6.
45. Reimer K.A., Lowe J.E., Rasmussen M.M., and Jennings R.B. The wave form phenomenon of ischemic cell death. I. Myocardial infarct size vs. duration of coronary occlusion in dogs. Circulation 56 (1977) 786
46. Nicholson D.W. From bench to clinic with apoptosis-based therapeutic agents. Nature 407 (2000) 810-816
47. Fischer U.M., Cox C.S.J., Laine G.A., Mehlhorn U., Bloch W., and Allen S.J. Induction of cardioplegic arrest immediately activates the myocardial apoptosis signal pathway. Am J Physiol 292 (2007) H1630-H1633
48. Malmberg M., Vähäsilta T., Saraste A., Kytö V., Kiss J., Kentala E., Kallajoki M., and Savunen T. Cardiomyocyte apoptosis and duration of aortic clamping in pig model of open heart surgery. Eur J Cardiothorac Surg 30 (2006) 480-484
49. Depre C., and Vatner S.F. Cardioprotection in stunned and hibernating myocardium. Heart Fail Rev 12 (2007) 307-317
50. Braunwald E., and Kloner R.A. The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation 66 (1982) 1146-1149
51. Kloner R.A., Bolli R., Marban E., Reinlib L., and Braunwald E. Medical and cellular implications of stunning, hibernation, and preconditioning. An NHLBI workshop. Circulation 97 (1998) 1848-1867
52. Piper H.M., Meuter K., and Schäfer C. Cellular mechanisms of ischemia-reperfusion injury. Ann Thorac Surg 75 (2003) S644-S648
53. Vinten-Johansen J., Jiang R., Reeves J.G., Mykytenko J., Deneve J., and Jobe L.J. Inflammation, proinflammatory mediators and myocardial ischemia-reperfusion Injury. Hematol Oncol Clin North Am 21 (2007) 123-145
54. Ambrosio G., Weissfeldt M.D., Jacobus W.E., and Flaherty J.T. Evidence of a reversible, radical-mediated component of reperfusion injury: reduction by recombinant human superoxide dismutase administered at the time of reflow. Circulation 75 (1987) 282
55. Karmazyn M., Gan X.T., Humphreys R.A., Yoshida H., and Kusumoto K. The myocardial Na(+)-H(+) exchange: structure, regulation, and its role in heart disease. Circ Res 85 (1999) 777-786
56. Kawata H., Sawatari K., and Mayer J.E. Evidence for the role of neutrophils in reperfusion injury after cold cardioplegic ischemia in neonatal lambs. J Thorac Cardiovasc Surg 103 (1992) 908-918
57. +-ATPase. Am J Physiol 252 (1987) H252-H257
58. Lopaschuk G.D., Wambolt R.B., and Barr R.L. An imbalance between glycolysis and glucose oxidation is a possible explanation for the detrimental effects of high levels of fatty acids during aerobic reperfusion of ischemic hearts. J Pharmacol Exp Ther 264 (1993) 135-144
59. Rosenkranz E.R., Okamoto F., Buckberg G.D., Robertson J.M., Vinten-Johansen J., and Bugyi H. Safety of prolonged aortic clamping with blood cardioplegia: aspartate enrichment of glutamate-blood cardioplegia in energy-depleted hearts after ischemic and reperfusion injury. J Thorac Cardiovasc Surg 91 (1986) 428-435
60. Kantor P.F., Dyck J.R., and Lopaschuk G.D. Fatty acid oxidation in the reperfused ischemic heart. Am J Med Sci 318 (1999) 3-14
61. Doenst T., Richwine T.R., Bray M.S., Frazier O.H., Goodwin G.W., and Taegtmeyer H. Insulin improves functional and metabolic recovery of reperfused working rat heart. Ann Thorac Surg 67 (1999) 1682-1688
62. Zaha V., Francischetti I., and Doenst T. Insulin improves postischemic recovery of function through PI3K in isolated working rat heart. Mol Cell Biochem 247 (2003) 229-232
63. Turcani M., and Rupp H. Etomoxir improves left ventricular performance of pressure-overloaded rat heart. Circulation 96 (1997) 3681-3686
64. Bretschneider H.J. Myocardial protection. Thorac Cardiovasc Surg 28 (1980) 295-302
65. Hearse D.J., Braimbridge M.V., and Jynge P. Protection of the ischemic myocardium: cardioplegia (1981), Raven Press, New York
66. Corvera JS, Kin H, Dobson GP, Kerendi F, Halkos ME, Katzmark S, Payne CS, Zhao ZQ, Guyton RAV-J, J. Polarized arrest with warm or cold adenosine/lidocaine blood cardioplegia is equivalent to hypothermic potassium blood cardioplegia. J Thorac Cardiovas Surg 2005;129:599-606.
67. Doenst T., Schlensak C., and Beyersdorf F. Cardioplegia in pediatric cardiac surgery - do we believe in magic?. Ann Thorac Surg 75 (2003) 1668-1677
68. Schlensak C., Doenst T., and Beyersdorf F. Clinical experience with blood cardioplegia. Thorac Cardiovasc Surg 46 (1998) 282-285
69. Oriaku G., Xiang B., Dai G., Shen J., Sun J., Lindsay W.G., Deslauriers R., and Tian G. Effects of retrograde cardioplegia on myocardial perfusion and energy metabolism in immature porcine myocardium. J Thorac Cardiovasc Surg 119 (2000) 1102-1109
70. Williams W.G., Rebeyka I.M., Tibshirani R.J., Coles J.G., Lightfoot N.E., Mehra A., Freedom R.M., and Trusler G.A. Warm induction blood cardioplegia in the infant. A technique to avoid rapid cooling myocardial contracture. J Thorac Cardiovasc Surg 100 (1990) 896-901
71. Guru V., Omura J., Alghamdi A.A., Weisel R., and Fremes S.E. Is blood superior to crystalloid cardioplegia? A meta-analysis of randomized clinical trials. Circulation 114 (2006) I331-I338
72. Demmy T.L., Biddle J.S., Bennet L.E., Walls J.T., Schmaltz R.A., and Curtis J.J. Organ preservation solutions in heart transplantation - patterns of usage and related survival. Ann Thorac Surg 63 (1997) 262-296
73. Doenst T., Borger M.A., Weisel R.D., Yau T.M., Maganti M., and Rao V. Relation between aortic cross-clamp time and mortality - not as straightforward as expected. Eur J Cardiothorac Surg 33 (2008) 660-665
74. Doenst T., Bothe W., and Beyersdorf F. Therapy with insulin in cardiac surgery: controversies and possible solutions. Ann Thorac Surg 75 (2003) S721-S728
75. Bothe W., Olschewski M., Beyersdorf F., and Doenst T. Glucose-insulin-potassium in cardiac surgery: a meta-analysis. Ann Thorac Surg 78 (2004) 1650-1657
76. Puskas F., Grocott H.P., White W.D., Mathew J.P., Newman M.F., and Bar-Yosef S. Intraoperative hyperglycemia and cognitive decline after CABG. Ann Thorac Surg 83 (2007) 1467-1473
77. Furnary A.P., Gao G., Grunkemeier G.L., Wu Y., Zerr K.J., Bookin S.O., Floten S., and Starr A. Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 125 (2003) 1007-1021
78. Lazar H.L., Chipkin S.R., Fitzgerald C.A., Bao Y., Cabral H., and Apstein C.S. Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events. Circulation 109 (2004) 1497-1502
79. van den Berghe G., Wouters P., Weekers F., Verwaest C., Bruyninckx F., Schetz M., Vlasselaers D., Ferdinande P., Lauwers P., and Bouillon R. Intensive insulin therapy in critically ill patients. N Engl J Med 345 (2001) 1359-1367
80. Ingels C., Debaveye Y., Milants I., Buelens E., Peeraer A., Devriendt Y., Vanhoutte T., Van Damme A., Schetz M., Wouters P.J., and Van den Berghe G. Strict blood glucose control with insulin during intensive care after cardiac surgery: impact on 4-years survival, dependency on medical care, and quality-of-life. Eur Heart J 27 (2006) 2716-2724
81. Doenst T., Wijeysundera D., Karkouti K., Zechner C., Maganti M., Rao V., and Borger M.A. Hyperglycemia during cardiopulmonary bypass is an independent risk factor for mortality in patients undergoing cardiac surgery. J Thorac Cardiovas Surg 130 (2005) 1144-1150
82. Gandhi G.Y., Nuttall G.A., Abel M.D., Mullany C.J., Schaff H.V., O'Brien P.C., Johnson M.G., Williams A.R., Cutshall S.M., Mundy L.M., Rizza R.A., and McMahon M.M. Intensive intraoperative insulin therapy versus conventional glucose management during cardiac surgery: a randomized trial. Ann Intern Med 146 (2007) 233-243
83. Booth G., Stalker T.J., Lefer A.M., and Scalia R. Elevated ambient glucose induces acute inflammatory events in the microvasculature: effects of insulin. Am J Physiol 280 (2001) E848-E856
84. Shann K.G., Likosky D.S., Murkin J.M., Baker R.A., Baribeau Y.R., DeFoe G.R., Dickinson T.A., Gardner T.J., Grocott H.P., O'Connor G.T., Rosinski D.J., Sellke F.W., and Willcox T.W. An evidence-based review of the practice of cardiopulmonary bypass in adults: a focus on neurologic injury, glycemic control, hemodilution, and the inflammatory response. J Thorac Cardiovasc Surg 132 (2006) 283-290
85. Bhatia A., Cadman B., and Mackenzie I. Hypoglycemia and cardiac arrest in a critically ill patient on strict glycemic control. Anaesth Analg 102 (2006) 549-551
86. Borger M.A., Ivanov J., Weisel R.D., Rao V., and Peniston C.M. Stroke during coronary bypass surgery: principal role of cerebral macroemboli. Eur J Cardiothorac Surg 19 (2001) 627-632
87. Smith K.S. Insulin and glucose in the treatment of heart disease. Br Med J 186 (1933) 693-696
88. Schmidt-Schweda S., and Holubarsch C. First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci 99 (2000) 27-35
89. Holubarsch C.J., Rohrbach M., Karrasch M., Boehm E., Polonski L., Ponikowski P., and Rhein S. A double-blind randomised, multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: The ERGO (etomoxir for the recovery of glucose oxidation) study. Clin Sci (Lond) 113 (2007) 205-212
90. Dobbins R.L., Szczepaniak L.S., Bentley B., Esser V., Myhill J., and McGarry J.D. Prolonged inhibition of muscle carnitine palmitoyltransferase-1 promotes intramyocellular lipid accumulation and insulin resistance in rats. Diabetes 50 (2001) 123-130
91. Tang W.H. Metabolic approach in heart failure: rethinking how we translate from theory to clinical practice. J Am Coll Cardiol 48 (2006) 999-1000
92. Fragasso G, Palloshi A, Puccetti P, Silipigni C, Rossodivita A, Pala M, Calori GA, O, Margonato A. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol 2006;48:992-8.
93. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Skene A, CH M, Braunwald E, Investigators M-T. Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial. Am Heart J 2006;151:1186.e1181-9.
94. Vedrinne J.M., Vedrinne C., Bompard D., Lehot J.J., Boissel J.P., and Champsaur G. Myocardial protection during coronary artery bypass graft surgery: a randomized, double-blind, placebo-controlled study with trimetazidine. Anesth Analg 82 (1996) 712-718
95. Tunerir B., Colak O., Alatas O., Besogul Y., Kural T., and Aslan R. Measurement of troponin T to detect cardioprotective effect of trimetazidine during coronary artery bypass grafting. Ann Thorac Surg 68 (1999) 2173-2176
96. Iskesen I., Saribulbul O., Cerrahoglu M., Var A., Nazli Y., and Sirin H. Trimetazidine reduces oxidative stress in cardiac surgery. Circ J 70 (2006) 1169-1173
97. Sodi-Pallares D., Bisteni A., Medrano G.A., Testelli M.R., and DeMichell A. The polarizing treatment of acute myocardial infarction. Dis Chest 43 (1963) 424-432
98. Taegtmeyer H. The use of hypertonic glucose, insulin, and potassium (GIK) in myocardial preservation. J Appl Cardiol 6 (1991) 255-259
99. Doenst T., and Taegtmeyer H. Ischemia-stimulated glucose uptake does not require catecholamines in rat heart. J Mol Cell Cardiol 31 (1999) 435-443
100. Kantor P.F., Lucien A., Kozak R., and Lopaschuk G.D. The anti-anginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 86 (2000) 580-588
101. McCormack J.G., Barr R.L., Wolff A.A., and Lopaschuk G.D. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation 93 (1996) 135-142
102. Bebernitz G.A., Aicher T.D., Stanton J.L., Gao J., Shetty S.S., Knorr D.C., Strohschein R.J., Tan J., Brand L.J., Liu C., Wang W.H., Vinluan C.C., Kaplan E.L., Dragland C.J., DelGrande D., Islam A., Lozito R.J., Liu X., Maniara W.M., and Mann W.R. Anilides of (R)-trifluoro-2-hydroxy-2-methylpropionic acid as inhibitors of pyruvate dehydrogenase kinase. J Med Chem 43 (2000) 2248-2257
103. Birand A., Kudaiberdieva G.Z., Byatyraliev T.A., Akgul F., and Usal A. Effects of trimetazidine on heart rate variability and left ventricular systolic performance in patients with coronary artery disease after percutaneous transluminal angioplasty. Angiology 48 (1997) 413-422
104. Di Pasquale P., Lo Verso P., Bucca V., Cannizzarro S., Scalzo S., Maringhini G., Rizzo R., and Paterna S. Effects of trimetazidine administration before thrombolysis in patients with anterior myocardial infarction: short-term and long-term results. Cardiovasc Drug Ther 13 (1999) 423-428
105. Clarke B., Wyatt K.M., and McCormack J.G. Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: evidence for an indirect mechanism. J Mol Cell Cardiol 28 (1996) 341-350
106. Cavallini L., Valente M., and Rigobello M.P. The protective action of pyruvate on recovery of ischemic rat heart: comparison with other oxidizable substrates. J Mol Cell Cardiol 22 (1990) 143-154
107. Bartels G.L., Remme W.J., Pillay M., Schonfeld D.H., and Kruijssen D.A. Effects of l-proprionylcarnitine on ischemia-induced myocardial dysfunction in men with angina pectoris. Am J Cardiol 74 (1994) 125-130
108. Lewis J.F., DaCosta M., Wargowich T., and Stacpoole P. Effects of dichloroacetate in patients with congestive heart failure. Clin Cardiol 21 (1998) 888-892
109. Saiki Y., Lopaschuk G.D., Dodge K., Yamaya K., Morgan C., and Rebeyka I.M. Pyruvate augments mechanical function via activation of pyruvate dehydrogenase complex in reperfused ischemic immature rabbit hearts. J Surg Res 79 (1998) 164-169
110. Desideri A., and Celegon L. Metabolic management of ischemic heart disease: clinical data with trimetazidine. Am J Cardiol 82 (1998) 50K-53K
111. Thadani U., Ezekowitz M., Fenney L., Chiang Y.K., and Ranolazine study group. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Circulation 90 (1994) 726-734